Literature DB >> 14739224

Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells.

Xiaomin Zheng1, Tim Beissert, Natasa Kukoc-Zivojnov, Elena Puccetti, Joachim Altschmied, Corinna Strolz, Simone Boehrer, Hilal Gul, Orinta Schneider, Oliver Gerhard Ottmann, Dieter Hoelzer, Reinhard Henschler, Martin Ruthardt.   

Abstract

Acute myeloid leukemia (AML) is characterized by the block of differentiation, deregulated apoptosis, and an increased self-renewal of hematopoietic precursors. It is unclear whether the self-renewal of leukemic blasts results from the cumulative effects of blocked differentiation and impaired apoptosis or whether there are mechanisms directly increasing self-renewal. The AML-associated translocation products (AATPs) promyelocytic leukemia/retinoic acid receptor alpha (PML/RAR alpha), promyelocytic leukemia zinc finger (PLZF)/RAR alpha (X-RAR alpha), and AML-1/ETO block hematopoietic differentiation. The AATPs activate the Wnt signaling by up-regulating gamma-catenin. Activation of the Wnt signaling augments self-renewal of hematopoietic stem cells (HSCs). Therefore, we investigated how AATPs influence self-renewal of HSCs and evaluated the role of gamma-catenin in the determination of the phenotype of HSCs expressing AATPs. Here we show that the AATPs directly activate the gamma-catenin promoter. The crucial role of gamma-catenin in increasing the self-renewal of HSCs upon expression of AATPs is demonstrated by (i) the abrogation of replating efficiency upon hindrance of gamma-catenin expression through RNA interference, and (ii) the augmentation of replating efficiency of HSCs upon overexpression of gamma-catenin itself. In addition, the inoculation of gamma-catenin-transduced HSCs into irradiated recipient mice establishes the clinical picture of AML. These data provide the first evidence that the aberrant activation of Wnt signaling by the AATP decisively contributes to the pathogenesis of AML.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14739224     DOI: 10.1182/blood-2003-09-3335

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

Review 2.  Role of RUNX1 in hematological malignancies.

Authors:  Raman Sood; Yasuhiko Kamikubo; Paul Liu
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

Review 3.  Wnt signaling in normal and malignant hematopoiesis.

Authors:  William Lento; Kendra Congdon; Carlijn Voermans; Marcie Kritzik; Tannishtha Reya
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-02-01       Impact factor: 10.005

Review 4.  CBP/Catenin antagonists: Targeting LSCs' Achilles heel.

Authors:  Yong-Mi Kim; Eun-Ji Gang; Michael Kahn
Journal:  Exp Hematol       Date:  2017-05-04       Impact factor: 3.084

5.  Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML.

Authors:  Nickolas Steinauer; Chun Guo; Chunfa Huang; Madeline Wong; Yifan Tu; Carl E Freter; Jinsong Zhang
Journal:  Blood Adv       Date:  2019-05-14

6.  Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells.

Authors:  Annette Romanski; Kerstin Schwarz; Maren Keller; Sarah Wietbrauk; Anja Vogel; Jessica Roos; Claudia Oancea; Boris Brill; Oliver H Krämer; Hubert Serve; Martin Ruthardt; Gesine Bug
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

7.  Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment.

Authors:  Xiaomin Zheng; Claudia Oancea; Reinhard Henschler; Malcolm A S Moore; Martin Ruthardt
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

8.  Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo.

Authors:  Chen Zhao; Jordan Blum; Alan Chen; Hyog Young Kwon; Seung Hye Jung; J Michael Cook; Anand Lagoo; Tannishtha Reya
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

9.  PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors.

Authors:  S Wojiski; F C Guibal; T Kindler; B H Lee; J L Jesneck; A Fabian; D G Tenen; D G Gilliland
Journal:  Leukemia       Date:  2009-03-26       Impact factor: 11.528

10.  Applications of microarray technology to Acute Myelogenous Leukemia.

Authors:  Rashmi S Goswami; Mahadeo A Sukhai; Mariam Thomas; Patricia P Reis; Suzanne Kamel-Reid
Journal:  Cancer Inform       Date:  2008-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.